| Outcome Measures: |
Primary: Number of Participants With Adverse Events (AEs), Number of Participants with: Treatment-emergent AEs Treatment-emergent AEs assessed as related to the study drug. Serious Adverse Events Deaths, Through study completion; over 14 days treatment and one week follow up. | Secondary: Plasma Concentrations of EPN-701., • Maximum plasma concentration of EPN-701 (Cmax) \[ng/mL\]., Through study completion; over 14 days treatment and one week follow-up.|Time to Maximum Plasma Concentration of EPN-701., Time to maximum plasma concentration of EPN-701 (Tmax) (h)., Through study completion; over 14 days treatment and one week follow-up. | Other: Change From Baseline to Day 15 in Circulating Biomarker: Undercarboxylated Matrix Gla Protein (MGP), (Pmol/L)., The percent change in circulating biomarker: Undercarboxylated MGP (pmol/L) levels from Day 1 (Baseline) to Day 15 was measured., Day 1 to Day 15|Change From Baseline to Day 22 in Circulating Biomarker: Undercarboxylated Matrix Gla Protein (MGP), (Pmol/L)., The percent change in circulating biomarker: Undercarboxylated MGP (pmol/L) levels from Day 1 (Baseline) to Day 22 was measured., Day 1 to Day 22|Mean Value of Circulating Biomarker: Undercarboxylated Matrix Gla Protein (MGP), (Pmol/L) at Day 22., The mean value of circulating biomarker: Undercarboxylated MGP (pmol/L) levels on Day 22 was measured., Day 22|Mean Measure of Circulating Biomarker: Undercarboxylated Matrix Gla Protein (MGP), (Pmol/L)., Mean value of circulating biomarker: Undercarboxylated MGP (pmol/L) levels on Day 15 was measured., Day 15
|
